Wall Street’s top picks for 2026: JPMorgan says a rare biopharma stock could more than triple ⊕
JPMorgan sees shares of Ultragenyx Pharmaceutical soaring more than 200% from current prices.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.